Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/Genentech’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity for Venclexta.

What you will learn in this content:

  • What is U.S. hematologist-oncologists’ awareness of and familiarity with Venclexta, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Venclexta, what are the reasons for prescribing, and how satisfied are they with Venclexta?
  • What promotional messages and activities are Roche/Genentech employing in support of the Venclexta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Venclexta tracking compared with other recent first-in-class product launches in the oncology market?

Methodology: ~75-100 U.S. hematologist-oncologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten surveyed specialists participate in a 30-minute follow-up qualitative interview.

Related reports: Venclexta Launch Tracking (US) Wave 1, Venclexta Launch Tracking (US) Wave 2, Derzalex/Emplicity Launch Tracking (US) Wave 3

Table of contents

  • Venclexta Launch Tracking (US) Wave 3
    • Key Findings
    • Benchmarking Venclexta Launch Success vs. the Competition
      • Unaided Awareness of Venclexta One Year Postlaunch Is Comparable to This Awareness One Month Postlaunch
    • Prescriber and Nonprescriber Profiles
      • Over Half of Prescribers and Even More Nonprescribers Do Not Know Venclexta's Cost
    • Venclexta Awareness and Perceptions
      • Unaided and Aided Awareness of Venclexta
      • Familiarity with Venclexta
      • Sources of Familiarity with Venclexta
      • Initial Reaction to and Interest in Venclexta
      • Impressions of Venclexta
      • Prescriber and Nonprescriber Profiles
    • Venclexta Trial and Use
      • Willingness to Prescribe Venclexta
      • Number of Patients Currently Receiving Venclexta
      • Reasons for Not Yet Prescribing Venclexta
        • Lack of Familiarity One of Two Main Reasons for Not Yet Prescribing Venclexta
      • Anticipated Venclexta Use
        • All Current Nonprescribers Intend to Prescribe Venclexta in the Future
      • Venclexta Performance on Key Attributes
        • Over Two-Thirds of Prescribers are Highly Satisfied with Venclexta
    • Effectiveness of Face-to-Face Detailing for Venclexta
      • Venclexta Sales Representative Frequency and Reach
        • Forty Percent of Survey Respondents Never Visited by a Venclexta Representative
      • Satisfaction with Venclexta Sales Representative
        • Majority of Physicians Visited by a Venclexta Sales Rep Highly Satisfied
      • Venclexta Message Recall
        • Venclexta Dosing Frequency Discussed More Often One Year Than One Month Postlaunch
    • Methodology
      • Primary Market Research Methodology
    • Appendix

Author(s): Dana Gheorghe

Dana Gheorghe, is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a in cellular biology and biochemistry from the University of Sheffield and a in Molecular Biology from the University of Edinburgh.

Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over th...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Epidemiology | Mature Markets Non-Hodgkin's Lymphoma

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimat...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment | Detailed, Expanded Analysis (US)

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggre...

View Details